Low within-and between-day variability in exposure to new insulin glargine 300 U/ml

被引：0

作者：

Becker, R. H. ^{[1
]}

Nowotny, I. ^{[1
]}

Teichert, L. ^{[1
]}

Bergmann, K. ^{[1
]}

Kapitza, C. ^{[2
]}

机构：

[1] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany

[2] Profil, Neuss, Germany

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

953

引用

页码：S390 / S390

页数：1

共 50 条

[21] Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
Lindauer, Klaus
Becker, Reinhard
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (01) : 1 - 10
[22] Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs
Fink, H.
Herbert, C.
Gilor, C.
DOMESTIC ANIMAL ENDOCRINOLOGY, 2018, 64 : 17 - 30
[23] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
Bogdanovic, M.
Fournier, M.
Vitezic, D.
VALUE IN HEALTH, 2018, 21 : S131 - S132
[24] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
Bogdanovic, M.
Krnel, Rados S.
Foumier, M.
VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
[25] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
Bogdanovic, M.
Mihajlovic, J.
Fournier, M.
VALUE IN HEALTH, 2018, 21 : S133 - S133
[26] A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine
Dailey, G.
Lavernia, F.
DIABETES OBESITY & METABOLISM, 2015, 17 (12): : 1107 - 1114
[27] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
Yang, K. -H.
Tseng, C. -T.
Chen, L. -C.
Chen, P. -C.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
[28] Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
Mader, Julia K.
Goelz, Stefan
Bilz, Stefan
Bramlage, Peter
Danne, Thomas
BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (04)
[29] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, Jennifer
White, John R., Jr.
ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) : 1153 - 1161
[30] Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats
Gilor, C.
Culp, W.
Ghandi, S.
do Carmo Emidio e Silva, J. A.
Ladhar, A.
Hulsebosch, S.
DOMESTIC ANIMAL ENDOCRINOLOGY, 2019, 69 : 19 - 29

← 1 2 3 4 5 →